27322774|t|The anti-apoptotic PON2 protein is Wnt / β-catenin - regulated and correlates with radiotherapy resistance in OSCC patients
27322774|a|Aberrant Wnt signaling and control of anti-apoptotic mechanisms are pivotal features in different types of cancer to undergo cell death programs. The intracellular human enzyme Paraoxonase-2 (PON2) is known to have anti-apoptotic properties in leukemia and oral squamous cell cancer (OSCC) cells. However, the distinct regulating pathways are poorly understood. First, we present a so far unknown regulation of PON2 protein expression through the Wnt / GSK3β / β-catenin pathway in leukemia and OSCC cells. This was confirmed via in silico analysis, promoter reporter studies and treatment of multiple cell lines (K562, SCC-4, PCI-13) with different Wnt ligands / inhibitors in vitro. Ex vivo analysis of OSCC patients revealed a correlation between PON2 and β-catenin expression in tumor tissue. Higher PON2 expression in OSCC is associated with relapse independently of treatment (e.g. surgery / radio -/ chemotherapy). These results emphasize the clinical impact of the newly described regulation of PON2 through Wnt / GSK3β / β-catenin. More importantly, the study revealed the fundamental finding of an overall Wnt / GSK3β / β-catenin dependent regulation of PON2 in different cancers, which was confirmed by systematic and multimethodological approaches. Thus, the herein presented mechanistic insight contributes to a better understanding of tumor specific escape from cell death strategies and suggests PON2 as a new potential biomarker for therapy resistance or as a prognostic tumor marker.
27322774	4	18	anti-apoptotic	T038	UMLS:C1512772
27322774	19	31	PON2 protein	T103	UMLS:C0755726
27322774	35	38	Wnt	T103	UMLS:C0753137
27322774	41	50	β-catenin	T103	UMLS:C0105770
27322774	53	62	regulated	T038	UMLS:C1327622
27322774	83	95	radiotherapy	T058	UMLS:C1522449
27322774	133	146	Wnt signaling	T038	UMLS:C1520113
27322774	162	176	anti-apoptotic	T038	UMLS:C1512772
27322774	231	237	cancer	T038	UMLS:C0006826
27322774	249	259	cell death	T038	UMLS:C0007587
27322774	274	287	intracellular	T082	UMLS:C0178719
27322774	288	293	human	T204	UMLS:C0086418
27322774	294	300	enzyme	T103	UMLS:C0014442
27322774	301	314	Paraoxonase-2	T103	UMLS:C1122373
27322774	316	320	PON2	T103	UMLS:C1122373
27322774	339	353	anti-apoptotic	T038	UMLS:C1512772
27322774	368	376	leukemia	T038	UMLS:C0023418
27322774	414	419	cells	T017	UMLS:C0007634
27322774	443	453	regulating	T038	UMLS:C1327622
27322774	521	531	regulation	T038	UMLS:C1327622
27322774	535	547	PON2 protein	T103	UMLS:C0755726
27322774	548	558	expression	T038	UMLS:C1171362
27322774	571	574	Wnt	T038	UMLS:C1520113
27322774	577	582	GSK3β	T103	UMLS:C0244988
27322774	585	594	β-catenin	T103	UMLS:C0105770
27322774	595	602	pathway	T038	UMLS:C1704259
27322774	606	614	leukemia	T038	UMLS:C0023418
27322774	624	629	cells	T017	UMLS:C0007634
27322774	657	672	silico analysis	T062	UMLS:C0936012
27322774	674	699	promoter reporter studies	T062	UMLS:C0242481
27322774	704	713	treatment	T058	UMLS:C0087111
27322774	726	736	cell lines	T017	UMLS:C0007600
27322774	738	742	K562	T017	UMLS:C1517631
27322774	744	749	SCC-4	T017	UMLS:C0007634
27322774	751	757	PCI-13	T017	UMLS:C0007634
27322774	774	777	Wnt	T103	UMLS:C0753137
27322774	778	785	ligands	T038	UMLS:C1749457
27322774	788	798	inhibitors	T103	UMLS:C0243077
27322774	817	825	analysis	T062	UMLS:C0936012
27322774	874	878	PON2	T103	UMLS:C1122373
27322774	883	892	β-catenin	T103	UMLS:C0105770
27322774	893	903	expression	T038	UMLS:C1171362
27322774	907	919	tumor tissue	T017	UMLS:C0475358
27322774	928	932	PON2	T103	UMLS:C0755726
27322774	933	943	expression	T038	UMLS:C1171362
27322774	996	1005	treatment	T058	UMLS:C0087111
27322774	1012	1019	surgery	T058	UMLS:C0543467
27322774	1022	1027	radio	T058	UMLS:C1522449
27322774	1031	1043	chemotherapy	T058	UMLS:C3665472
27322774	1113	1123	regulation	T038	UMLS:C1327622
27322774	1127	1131	PON2	T103	UMLS:C1122373
27322774	1140	1143	Wnt	T103	UMLS:C0753137
27322774	1146	1151	GSK3β	T103	UMLS:C0244988
27322774	1154	1163	β-catenin	T103	UMLS:C0105770
27322774	1206	1225	fundamental finding	T033	UMLS:C0243095
27322774	1240	1243	Wnt	T103	UMLS:C0753137
27322774	1246	1251	GSK3β	T103	UMLS:C0244988
27322774	1254	1263	β-catenin	T103	UMLS:C0105770
27322774	1274	1284	regulation	T038	UMLS:C1327622
27322774	1288	1292	PON2	T103	UMLS:C1122373
27322774	1306	1313	cancers	T038	UMLS:C0006826
27322774	1353	1372	multimethodological	T170	UMLS:C0969625
27322774	1473	1478	tumor	T038	UMLS:C0027651
27322774	1500	1510	cell death	T038	UMLS:C0007587
27322774	1535	1539	PON2	T103	UMLS:C1122373
27322774	1559	1568	biomarker	T201	UMLS:C0005516
27322774	1573	1580	therapy	T058	UMLS:C0087111
27322774	1600	1610	prognostic	T170	UMLS:C0220901
27322774	1611	1623	tumor marker	T103	UMLS:C0041365